Scilex Holding Company SCLX

Company Overview

Scilex Holding Company is a specialty biopharmaceutical company focused on developing and commercializing non-opioid pain management therapies. The company operates within the pharmaceutical and biotechnology industries, with an emphasis on acute pain, neuropathic pain, musculoskeletal conditions, and other chronic pain indications. Scilex’s commercial and development activities are primarily centered on prescription pain therapeutics designed to address unmet clinical needs while reducing dependence on opioid-based treatments.

The company’s principal revenue drivers include marketed pain products and licensing-related activities tied to its proprietary drug delivery technologies and product portfolio. Its commercial products have included ZTlido, a lidocaine topical system for post-herpetic neuralgia, while development-stage assets have targeted migraine, low back pain, fibromyalgia, and osteoarthritis-related conditions. Scilex evolved through a series of acquisitions, licensing arrangements, and corporate restructuring transactions, including its historical association with Sorrento Therapeutics, Inc. and its later public listing through a special purpose acquisition transaction. The company has positioned itself around differentiated delivery systems, branded pain therapeutics, and a broader strategy focused on non-opioid pain care.